ATLANTA--(

亚特兰大--(

BUSINESS WIRE

商业热线

)--

)--

OMNY Health

OMNY健康

, the leading healthcare ecosystem for compliant real-world data insights at scale, and

，领先的医疗保健生态系统，可大规模提供符合法规的真实世界数据见解，以及

Scipher Medicine

科幻医学

, which has the world’s largest immunology clinico-transcriptomics data set and is focused on advancing precision medicine with proprietary AI network biology solutions, today announced a partnership to advance precision medicine efforts for immunology.

，拥有世界上最大的免疫学临床转录组学数据集，专注于通过专有的AI网络生物学解决方案推进精准医学，今天宣布建立合作伙伴关系，以推进精准医学在免疫学方面的努力。

This collaboration marks a significant leap forward in the fight against autoimmune diseases, integrating transcriptomic data from Scipher Medicine with OMNY Health's vast EHR network that reaches more than 80 million patients. OMNY Health’s network includes data from nearly 250,000 patients with rheumatoid arthritis, covering key metrics such as functional status, lab values (ESR, CRP), joint counts, CDAI, and DAS28, which enables comprehensive tracking of patient outcomes and disease progression..

这项合作标志着在对抗自身免疫性疾病方面取得了重大飞跃，将Scipher Medicine的转录组数据与OMNY Health庞大的EHR网络整合在一起，覆盖了8000多万患者。OMNY Health的网络包括近250000名类风湿性关节炎患者的数据，涵盖功能状态，实验室值（ESR，CRP），关节计数，CDAI和DAS28等关键指标，可全面跟踪患者预后和疾病进展。。

This partnership unlocks a wealth of information for researchers and drug developers. By combining the detailed clinical data within OMNY Health's network with the rich genomic insights from PrismRA, a personalized blood test for rheumatoid arthritis, researchers may gain a holistic view of the patient journey.

。通过将OMNY Health网络中的详细临床数据与PrismRA（一种针对类风湿性关节炎的个性化血液检测）的丰富基因组见解相结合，研究人员可能会获得患者旅程的整体视图。

This deeper understanding will fuel the development of more targeted therapies and improve overall patient outcomes. Scipher Medicine has tested over 40,000 rheumatoid arthritis patients using PrismRA, which includes information on treatment response and is the only approved classifier by CMS in the United States..

这种更深入的理解将推动更有针对性的治疗方法的发展，并改善患者的整体预后。Scipher Medicine已经使用PrismRA测试了40000多名类风湿性关节炎患者，其中包括治疗反应的信息，并且是美国CMS唯一批准的分类器。。

“At OMNY Health, we are steadfast in our belief that highly targeted therapies and treatments for disease are the key to improving healthcare outcomes,” said Dr. Mitesh Rao, Founder and CEO of OMNY Health. “Nearly

“在OMNY Health，我们坚信高度针对性的疾病治疗和治疗是改善医疗保健效果的关键，”OMNY Health创始人兼首席执行官Mitesh Rao博士说。“差不多

50 million Americans

5000万美国人

suffer from autoimmune diseases, and their patient experiences hold valuable insights that, if extracted, could help drive advancements in precision medicine.”

患有自身免疫性疾病，他们的患者经历具有宝贵的见解，如果提取出来，可以帮助推动精准医学的进步。”

“We recognized the significant role that clinico-transcriptomic data plays in both treatment decisions and bringing precision medicine to patients,” said Dr. Reginald Seeto, President and CEO of Scipher Medicine. “Patients deserve clarity and personalized evidence-based answers when navigating individual treatment options.

Scipher medicine总裁兼首席执行官雷金纳德·西托（ReginaldSeeto）博士说：“我们认识到临床转录组数据在治疗决策和为患者带来精准医学方面所起的重要作用。”。“在浏览个人治疗方案时，患者应该得到清晰和个性化的循证答案。

By partnering with OMNY Health, we will enable clinicians and researchers to make data-driven decisions that ultimately reduce the risk to patients.”.

通过与OMNY Health合作，我们将使临床医生和研究人员能够做出数据驱动的决策，最终降低患者的风险。”。

In addition, OMNY Health’s partners within life sciences gain access to the valuable clinico-transcriptomic datasets of Scipher Medicine’s PrismRA-tested patients. Precision medicine is heavily reliant on data, with biomarker-dependent drugs making up

此外，OMNY Health在生命科学领域的合作伙伴可以访问Scipher Medicine的PrismRA测试患者的有价值的临床转录组数据集。精准医学严重依赖数据，生物标志物依赖性药物构成

42

42

percent

百分比

of approvals

批准数量

by the FDA. By providing drug developers with diverse, multi-modal datasets like those from OMNY Health, they can more effectively identify new patient groups and expand the availability of precision medicine therapies in the market.

由FDA提供。通过为药物开发人员提供各种各样的多模式数据集，如OMNY Health的数据集，他们可以更有效地识别新的患者群体，并扩大市场上精准药物疗法的可用性。

This announcement follows the launch of OMNY Health's GLP-1 database of more than 600,000 datasets, which enhances clinical research on GLP-1 medications, specifically for pediatrics and social determinants of health. OMNY Health continues to forge industry partnerships that support research programs across many facets of healthcare..

此前，OMNY Health推出了包含60多万个数据集的GLP-1数据库，该数据库增强了GLP-1药物的临床研究，特别是针对儿科和健康的社会决定因素。OMNY Health继续建立行业合作伙伴关系，支持医疗保健各个方面的研究计划。。

About OMNY Health

OMNY Health™ is a national data ecosystem connecting the world of healthcare to fuel partnerships that improve clinical outcomes and drive patient care. OMNY’s dynamic partnerships with specialty health networks, healthcare systems, academic medical centers, and integrated delivery networks span all fifty states and cover over 75 million patient lives.

OMNY Health™是一个国家数据生态系统，将医疗保健领域与改善临床结果和推动患者护理的伙伴关系联系起来。OMNY与专业健康网络、医疗保健系统、学术医疗中心和综合交付网络的动态合作伙伴关系跨越了所有五十个州，覆盖了7500多万患者的生命。

The company’s comprehensive data layer powers health tech companies to drive the next generation of innovation. The platform serves as a centralized resource for life sciences and healthcare provider groups to facilitate mutually-beneficial data sharing and research collaboration at scale, fueling innovation where patients need it the most.

该公司的综合数据层为健康技术公司推动下一代创新提供了动力。该平台是生命科学和医疗保健提供者团体的集中资源，可促进大规模互利的数据共享和研究合作，推动患者最需要的创新。

OMNY Health’s data ecosystem now reflects more than seven years of historical data encompassing more than 2 billion clinical notes from 300,000+ providers across 200+ specialties - and is growing. To learn more about how OMNY Health transforms lives and drives patient care by connecting providers and life sciences companies through data, visit .

OMNY Health的数据生态系统现在反映了七年多的历史数据，包括来自200多个专业的300000多家供应商的20多亿份临床记录，并且正在增长。要了解更多有关OMNY Health如何通过数据连接提供商和生命科学公司来改变生活并推动患者护理的信息，请访问。

www.omnyhealth.com

www.omnyhealth.com

.

.

About Scipher Medicine

关于Scipher Medicine

Scipher Medicine is driving the probability of success at each stage of drug development from discovery to commercialization by leveraging AI with network biology and proprietary data, through our SPECTRA Rx and Dx platforms. Scipher has the industry’s largest RA clinic- genomic data asset and biobank in addition to EMR data for over 3 million rheumatology patients.

Scipher Medicine通过我们的SPECTRA Rx和Dx平台，利用人工智能与网络生物学和专有数据，推动药物开发从发现到商业化的每个阶段的成功概率。Scipher拥有业界最大的RA诊所-基因组数据资产和生物库，以及300多万风湿病患者的EMR数据。

For more information, please visit .

有关更多信息，请访问。

www.sciphermedicine.com

www.sciphermedicine.com

.

.

About PrismRA®

关于PrismRA®

PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual’s molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, the world’s largest selling drug class, so non-responders can be prescribed alternative effective therapy and avoid unnecessary dose escalations or drug cycles.

PrismRA是一项革命性的血液测试，将精准医学应用于治疗类风湿性关节炎，全球有2000万患者受到影响。从常规抽血中，PrismRA测试分析了个体的分子特征，有助于确定谁不太可能对TNFi疗法（世界上最大的销售药物类别）产生充分反应，因此可以为无反应者开出替代有效疗法，避免不必要的剂量增加或药物周期。

Providers now have objective data to inform therapeutic decision-making and give patients the best chance of achieving treatment targets and improving clinical outcomes. For more information, please visit .

。有关更多信息，请访问。

PrismRA.com.

PrismRA.com。